870603-16-0

XL-281 (BMS-908662) is an orally active inhibitor for RAF kinase, with IC50s of 2.6, 4.5 and 6 nM, for CRAF, B-RAF, and B-RAFV600E, respectively. XL-281 exhibits antitumor activity[1].

c-Raf: 2.6 nM (IC₅₀); B-Raf: 4.5 nM (IC₅₀); B-Raf^V600E: 6 nM (IC₅₀)

[1] Dickson MA, et al., Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):349-56. DOI:10.1007/s10637-014-0191-5